Announcement
Deepverge PLC : U.S. launch of Skin Trust Club at Beauty Connect
RNS Number : 0057S
Deepverge PLC
11 November 2021
11 November 2021
DeepVerge PLC
("DeepVerge" or "the Company")
U.S. launch of Skin Trust Club at Beauty Connect in Los Angeles
B2C and B2B offerings unveiled
DeepVerge (LSE:DVRG.L), announces that the Skin Trust Club is live in the U.S. following its launch to industry at Beauty Connect, Los Angeles on 4-5 November 2021. The U.S. launch is part of a five-event roadshow to industry that is unveiling what Skin Trust Club is all about and illustrating its power as a new game changing service in the skin health business.
At industry events in London (Pure Beauty) on 28 October 2021, Los Angeles (Beauty Connect) 4-5 November 2021, Boston (Microbiome Connect) 17-18 November 2021, Amsterdam (Microbiome Connect) 7-8 December 2021 and San Francisco (Personalised Beauty Summit) 30-31 March 2021, scientists from DeepVerge are briefing industry on the facets of the Skin Trust Club service:
· A science based personalised skincare service for consumers;
· A clinical trial for industry where microbiome samples are collected before, during and after trials to see granular effects;
· A personalised shopping experience where Skin Trust Club customers only see products relevant to their skin with science and AI based recommendations for skin health routines; and
· A databank of thousands of skin sample data with AI models constantly learning about different types of skin and the effects of lifestyle, medications, environment and skin products and ingredients on that skin.
With Skin Trust Club laboratories in York, UK, and Delaware, US, and a new laboratory in Cork, Ireland, coming online to serve the EU market, Skin Trust Club is available in two major markets - UK and US - and will also be available in selected EU countries by the end of this year.
Gerard Brandon, CEO of DeepVerge, commented:
"With the service now available across all platforms and an in-house back office system that has been tested at scale, we are now showing the power of the service as a B2C offering but also as a game changing B2B offering. The industry is realising that with Skin Trust Club, the Holy Grail of personalised beauty and skincare is here. Our partner programme is seeing leading brands sign up to sell the service as part of their product/service offerings, to use the service as part of their clinical trials and finally to see the impact the largest skin microbiome database in the world can have on moving skin science and their research forward.
"With Skin Trust Club, we've had moments where servers were overloaded with demand and where partners are imploring us to move into their core markets quicker than we initially planned. Thankfully by making the strategic decision to build everything in-house - sequencing, software, AI - thereby controlling the normalisation of the service, we have the flexibility to move fast to scale. With exciting events this year and a roadmap that includes replicating the service for scalp, hands, legs and feet, both industry and consumers know that the future of skincare is based on deep science.
"As a business, we are also seeing the full impact of the synergies within our business where our Labskin and Data/AI companies are working hand-in-hand to create a new service that the Board believes will have a profound effect on the skin health industry worldwide."
For further information please contact:
|
DeepVerge plc |
Gerard Brandon, CEO
|
+44 (0) 7340 055 648 |
|
SPARK Advisory Partners Limited (Nominated Adviser)
|
Neil Baldwin/Andrew Emmott |
+44 (0) 113 370 8974 |
|
Turner Pope Investments (TPI) Limited (Broker) |
Andy Thacker/James Pope |
+44 (0) 20 3657 0050 |
About DeepVerge plc (www.deepverge.com)
DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.
Labskin (Life Science Division)
Labskin have been pioneering the development of a laboratory grown human skin platform for more than 13 years and is the only commercially available lab-grown full thickness human skin model that naturally mimic the skin's microbiome. With top 20 global consumer health and skincare clients, thousands of industry tests, the good and bad bacteria that naturally exists on human skin is present on Labskin when testing skin care, cosmetics, health care, drug delivery or wound care products. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing skincare products, that shows the positive or negative impact on skin's natural microflora.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRADKKBBOBDDKDD
;